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Abstract
Background Studies addressing the anti-inflammatory properties of citrate dialysate enrolled patients in both hemodialysis 
(HD) and hemodiafiltration (HDF), the latter not adjusted for adequate convective exchange. This is a potential source of 
confounding in that HDF itself has anti-inflammatory effects regardless of the buffer, and optimal clinical outcomes are 
related to the amount of convection.
Methods To distinguish the merits of the buffer from those of convection, we performed a 6-month, prospective, randomized, 
crossover AB-BA study. Comparisons were made during the 3-month study period of on-line HDF with standard dialysate 
containing three mmol of acetic acid (OL-HDFst) and the 3-month of OL-HDF with dialysate containing one mmol of cit-
ric acid (OL-HDFcit). Primary outcome measure of the study was interleukin-6 (IL-6). Klotho, high sensitivity C-reactive 
protein (hsCRP), fetuin and routine biochemical parameters were also analyzed.
Results We analyzed 47 patients (mean age 64 years, range 27-84 years) enrolled in 10 participating Nephrology Units. 
Convective volumes were around 25 L/session with 90 percent of sessions > 20 L and ß2-microglobulin reduction rate 76% 
in both HDFs. Baseline median IL-6 values in OL-HDFst were 5.6 pg/ml (25:75 interquartile range IQR 2.9:10.6) and in 
OL-HDFcit 6.6 pg/ml (IQR 3.4:11.4 pg/ml). The difference was not statistically significant (p 0.88). IL-6 values were lower 
during OL-HDFcit than during OL-HDFst, both when analyzed as the median difference of overall IL-6 values (p 0.02) and 
as the median of pairwise differences between the baseline and the 3-month time points (p 0.03). The overall hsCRP values 
too, were lower during OL-HDFcit than during OL-HDFst (p 0.01). Klotho levels showed a time effect (p 0.02) and the 
increase was significant only during OL-HDFcit (p 0.01).
Conclusions Citrate buffer modulated IL-6, hsCRP and Klotho levels during high volume OL-HDF. These results are not 
attributable to differences in the dialysis technology that was applied and may suggest a potential biological effect of citrate 
on CKD-associated inflammatory state. ClinicalTrials.gov identifier NCT02863016.
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Introduction
Bicarbonate dialysate contains 3–4 mmol/L of acetate to sta-
bilize the pH. As the patient’s pre-dialysis blood levels of 
this anion are usually lower than 0.1 mmol/L, during treat-
ment the dialysate-blood gradient induces a strongly positive 
acetate mass balance and an increase in acetate plasma levels 
[1] with potentially negative effects on micro-inflammation 
[2]. Therefore, acetate-free dialysate may reduce the inflam-
matory status induced by extracorporeal treatments [1, 3].
Citric acid is an alternative dialysis buffer that is con-
verted into its anion citrate in the body. The first clinical 
experience with citrate dialysate in chronic dialysis dates 
back to 20 years ago [4]. During the long time span since 
then, positive effects of citrate have been reported, particu-
larly on anticoagulation and dialysis efficiency [5–8].
Moreover, citrate has clear anti-inflammatory properties 
in vitro [9, 10] and in various biological systems [11–13]. 
With regard to serum markers of inflammation, results 
are not so straightforward. Some studies found a reduc-
tion of  beta2-microglobulin (ß2M) and/or high sensitivity 
C-reactive protein (hsCRP) and/or interleukin 6 (IL-6) 
[13–17], while others showed negative results [18–20]. 
Many of these studies bear methodological weaknesses 
such as short and not randomized study design and/or few 
retrieved data sets. Moreover, some studies enrolled both 
patients treated with hemodialysis (HD) and on-line hemo-
diafiltration (OL-HDF) performed both in pre- or post-dilu-
tion with inadequate convection volumes. This is a poten-
tial source of confounding in that OL-HDF may modulate 
micro-inflammation better than HD does [21–25] and, fol-
lowing the seminal paper by Maduell et al. [26], optimal 
clinical outcomes of OL-HDF are related to the amount of 
convection [27, 28]. Finally, long-term survival of dialy-
sis patients treated with HD or HDF and citrate dialysate 
has recently been investigated in large retrospective stud-
ies [29–31], whose favorable results have been commented 
upon in an editorial [32]. Since inflammation is a powerful 
predictor of mortality, it is relevant to analyze the relation-
ship between citrate and inflammation taking into account 
confounders, namely dialysis techniques.
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In this prospective analysis, we aimed at assessing how the 
3-month use of an acetate-free, 1 mmol citrate-dialysate would 
affect the inflammatory marker IL-6. Fetuin-A and Klotho, 
direct and indirect vascular calcification inhibitors, respec-
tively, were also analyzed [33]. Comparisons were made in 
post-dilution OL-HDF pointing at convective exchanges as 
high as those suggested by current gold standards.
Methods
The Hephaestus study was a prospective, randomized, clini-
cal study involving patients under dialysis treatment in Ita-
ly’s Tuscany and Piedmont regions. The study procedures 
adhere to the tenets of the Declaration of Helsinki. Each 
participant provided written informed consent and the ethics 
committee of the participating centers approved the study 
protocol. Based on the remarks of the ethics committee, the 
presence of randomization and cross-over made it necessary 
to change the study type from observational (as registered in 
clinicalTrials.gov) to interventional. Outcomes of the study 
were detailed and finalized, accordingly. The primary objec-
tive was to assess the effect of high volume citrate OL-HDF 
(OL-HDFcit) compared with standard high volume OL-HDF 
(OL-HDFst) on the inflammatory state of prevalent dialysis 
subjects. The primary outcome was the change in the inflam-
matory marker IL-6 in three months. This time span proved 
adequate to capture variations in circulating cytokines due to 
different dialysis techniques [21, 22]. Key outcome was also 
feasibility of obtaining optimal convective volumes and OL-
HDF efficiency in removing small and medium molecules. A 
novel parameter of this study was the assessment of fetuin-A 
and Klotho during OL-HDFst vs. OL-HDFcit. Routine bio-
chemistry, e.g., hsCRP, divalent ions and acid–base param-
eters were also analyzed.
Study design
This was a multicenter, cohort, prospective, 6-month ran-
domized two-arm crossover study (AB or BA). After a 
1-month run-in period in OL-HDF, patients were centrally 
randomized to two groups. AB group patients were treated 
with OL-HDFst for 3 months and then were transferred to 
OL-HDFcit for a further period of 3 months. BA group 
patients were treated in the reverse order. The dialysis tech-
nique was assigned with a 1:1 ratio by means of a computer-
generated random list and randomization was stratified by 
dialysis centers.
Study population
We enrolled clinically stable patients aged > 18 years on 
dialysis treatment for at least 6 months. Internal vascular 
access (fistula or prosthesis) had to allow real blood flow 
of at least 250 ml/min and re-circulation below 10%. We 
excluded subjects with ongoing infections or recent hospi-
talizations or with clinically relevant residual renal function 
or with poor life expectancy due to metastatic cancer, severe 
cirrhosis and AIDS. Patients with an indwelling central 
venous catheter (CVC) were excluded due to CVC greater 
infectious risk than internal vascular access.
Treatment procedures
OL-HDFs were carried out with monitors provided with 
transmembrane pressure (TMP) biofeedback ultracontrol 
and with selectBag concentrates (Baxter International Inc., 
Medolla, Italy). Citrate acid concentrate contained 1 mmol 
of citric acid and 0 mmol of acetic acid; standard concen-
trate consisted of 3 mmol of acetic acid and 0 mmol of cit-
rate. The nominal concentrations of other constituents of 
the dialysate (D) were Na 140, Cl 108-110, K 2-3, HCO3 
32-34, Ca 1.5, Mg 0.5 mmol/l, glucose 1 gr/l. Two centers 
recruiting 10 patients utilized CaD 1.65 mmol/l.
Patients were treated with synthetic polyamide or 
polysulphone high-flux dialyzers. OL-HDFs were per-
formed with ultrapure dialysis fluids, defined as bacterial 
count < 0.1 CFU/ml and endotoxin < 0.03 EU/ml according 
to the Italian guidelines [34]. The microbiological water 
quality of the dialysis fluid was regularly monitored. Anti-
coagulation was performed with low molecular weight hepa-
rin before treatment. All patients were on a thrice-weekly 
treatment schedule. Dialysis prescription aimed at obtaining 
convective exchanges > 20 lt/session. Besides citrate, par-
ticipating centers did not have to change dialysis parameters 
before and after switching.
Study variables
Study variables were collected in the midweek dialysis ses-
sion at baseline and thereafter in the middle and at the end 
of each AB or BA study period (e.g. 6, 12, 18 and 24-week 
time points). Monitor-derived parameters included effec-
tive treatment time, total processed blood, dialysate flow 
rate (Qd), total infusion (Qinf), early (20’) and hourly TMP, 
and eKTV (ionic dialysance). We obtained blood flow rate 
(Qb) by total processed blood and effective treatment time. 
Pre-post treatment body weight (BW) were also recorded. 
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Patients’ age, anthropometric data and comorbidities were 
assessed using medical records and patient interviews at 
enrollment. Comorbidities were recorded using the Charl-
son Comorbidity Index (CCI). To account for the age effects, 
one point was added to the CCI score for each decade of 
life over the age of 50 [35]. Body mass index (BMI) was 
calculated as body weight/height2 (kg/m2). Pre-treatment 
hsCRP, ß2M, pH, bicarbonate  (HCO3), ionized Calcium 
 (Ca++), Phosphate  (PO4), Magnesium (Mg), immunoreactive 
parathyroid hormone (iPTH), Alkaline Phosphatase (Alk 
Phos) and post-treatment activated partial thromboplastin 
time (aPTT) were performed locally by standard procedures. 
Pre-treatment serum IL-6, fetuin and klotho were centralized 
in the University of Piemonte Orientale (UPO) laboratory of 
physiology that was blind to the treatments. Commercially 
available ELISA kits were used for serum determination 
of IL-6 (Thermofisher Scientific, Waltham, MA), Fetuin 
(Cloud-Clone Corporation, Katy, TX) and soluble Klotho 
(IBL-America, Minneapolis, MN).
Statistics
Sample size estimation: the outcome variable considered 
for sample size estimation was IL-6. Assuming that in com-
parison with standard dialysate the citrate buffered dialysate 
would have reduced IL-6 by 20% over 3 months, we cal-
culated that the inclusion of 45 patients would have con-
ferred an 80% power to demonstrate a statistically significant 
reduction of IL-6 (α = 0.05, one-tailed test). To account for 
a 15% dropout rate, we included 53 subjects in the study.
To determine whether parameters were normally distrib-
uted, a Kolmogoroff-Smirnoff test was performed.
Accordingly, data were expressed as mean ± stand-
ard deviation (SD), median and 25:75 interquartile range 
(IQR) or as percent frequency (%). Between- and within-
group comparisons were made by the Wilcoxon test, the 
T Test, repeated measures of ANOVA with Tukey–Kramer 
Multiple-Comparison Test or Chi Square Test, as appropri-
ate. For all parameters, we compared the values obtained 
in OL-HDFst and OL-HDFcit; we analyzed trend by pair-
wise differences between the T2-T0 time points. For miss-
ing data, we used the average of the two closest values or 
the last observation carried forward method for imputation. 
Calculations were made using SPSS for Windows Version 
25, Chicago, Illinois – US.
Results
During the calendar years 2016-2018, we enrolled 53 
patients from 10 Italian regional dialysis centers, six in Tus-
cany and four in Piedmont. Randomization was effective, 
27 patients were randomized to treatment sequence stand-
ard-citrate dialysate and 26 to treatment sequence citrate-
standard dialysate. Period and carry-over effects were not 
significant so the patient differences between the two periods 
were used for analyses. Therefore, comparisons were made 
at baseline (T0), after 6 weeks (T1) and after 12 weeks (T2) 
in the 3 months of OL-HDFst and OL-HDFcit, respectively. 
Six patients (11% of the 53 enrolled) dropped out, five on 
OL-HDFst and one on OL-HDFcit. Reasons for dropping 
out in the OL-HDFst group were withdrawal of consent, 
transfer to another Center, non-fatal myocardial infarction 
(two) and thrombosis of vascular access. The patient on 
OL-HDFcit dropped out because of sepsis due to peripheral 
vascular disease.
Table 1  Baseline characteristics in the randomized and fully analyzed 
cohorts
Cohort N 53 N 47
Men/women (n) 37/16 32/15
Age (years) 62.9 ± 13.7 63.6 ± 13.6
dialytic vintage (years) 6.9 ± 6.5 7.3 ± 6.1
height (cm) 170.5 ± 7.4 170.0 ± 7.6
Body weight (Kg) 71.7 ± 17.2 70.7 ± 17.0
BMI 24.5 ± 4.7 24.2 ± 4.7
BSA 1.9 ± 0.2 1.8 ± 0.2






Renal cancer 6 6
Undefined 28 26
Comorbidities (%)
Chronic heart failure 23 17
Myocardial infarction 21 19
Cerebro-vascular disease 6 6
Peripheral arterial disease 21 17
Diabetes 15 13
Cancer 8 9
Charlson Comorbidity Index 5.2 ± 2.1 5.1 ± 2.0
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Patients’ characteristics (Table 1)
The characteristics of the fully analyzed population (n 47) 
did not differ from the randomized one (n 53). Men made 
up a clear majority. The wide range of age (27–84 year) 
and weight (38-125 kg) of patients testifies that centers 
did not adopt restrictions on enrollment. Excluding age, 
Charlson comorbidity Index was 3.2 and 3.1 in the 2 popu-
lations, respectively, with dialytic state accounting for two 
points.
IL‑6 (Fig. 1)
Baseline (T0) median IL-6 values were 5.6 pg/ml (IQR 
2.9:10.6) and 6.6 pg/ml (IQR 3.4:11.4) in the OL-HDFst 
and OL-HDFcit allocation arms, respectively, and the 
difference was not significant (Wilcoxon, p 0.88). At 
time point T1 (6 weeks) and T2 (12 weeks) IL-6 val-
ues increased to 7.5 pg/ml (IQR 1.7:12.1) and to 7.0 pg/
ml (IQR 2.3:11.2) during OL-HDFst, and decreased to 
6.5  pg/ml (IQR 2.6:9.6) and 4.4  pg/ml (IQR 3.0:8.1) 
during OL-HDFcit. During the 3-month-study-period, 
IL-6 increased by 12% and decreased by 20% during 
OL-HDFst and OL-HDFcit, respectively. The median 
Fig. 1  Box plots of IL-6 values 
at time points T0 (Baseline), T1 
(6 weeks) and T2 (12 weeks). 
Standard OL-HDF (Black box) 
and citrate OL-HDF (gray box). 
Boxes identify 25 and 75 per-
centiles, vertical lines Min and 
Max values and horizontal line 
inside the box median values. 
For statistics see text
Fig. 2  Klotho mean values at 
time points T0 (Baseline), T1 
(6 weeks) and T2 (12 weeks). 
Black line standard OL-HDF, 
gray line citrate OL-HDF. For 
statistics see text
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difference of overall IL-6 values during OL-HDFst and 
OL-HDFcit (-0.56 pg/ml, 95% Confidence Interval CI 
-1.05:-0.07) was significant (p 0.024), as it was (p 0.029) 
the median of pairwise differences between the T2-T0 
time points (− 1.54 pg/ml, CI − 3.2:− 0.1).
Klotho (Fig. 2) and hsCRP
Baseline Klotho levels were 326 ± 235  pg/ml and 
306 ± 240  pg/ml during OL-HDFst and OL-HDFcit, 
respectively, and the difference was not statistically sig-
nificant (p 0.24). Values increased to 336 ± 252 pg/ml and 
340 ± 227 pg/ml at time points T1 and T2 during OL-HDFst 
and to 326 ± 221 pg/ml and 352 ± 216 pg/ml during OL-
HDFcit. The time effect by Anova was significant (p 0.015) 
and the increase was significant only during OL-HDFcit 
(T2-T0 comparison by Tukey, p 0.01). Unfortunately, we 
have hsCRP data from only 30 patients because not all cent-
ers routinely measured this parameter. The median hsCRP 
values were 1.68 mg/l (IQR 0.44:3.89) in OL-HDFst and 
1.37 mg/l (0.45:2.78) in OL-HDFcit. The median difference 
− 0.3 (CI − 0.58:− 0.02) was highly significant by Wilcoxon 
(p 0.009).
Technical parameters (Table 2)
Regardless of the buffer, all dialysis Centers performed OL-
HDFs according to the highest standards. Mean convection 
volumes were > 20 L in the overwhelming majority of treat-
ments, compared to not particularly elevated average effec-
tive Qb values. Average TMPs were within the safe range 
at both the beginning and end treatments, as was percent 
filtration fraction. The end treatment aPTT was within the 
normal range in both procedures.
Dialysis efficiency (Table 3)
ß2 reduction rate was consistent in both treatments. 
Table 2  Technical parameters
*Comparisons between the 141 treatments (47 patients, three time points) in both OL-HDFst and OL-
HDFcit
OL-HDFst OL-HDFcit St vs Cit p T2-T0 
Paired 
means p
Qconv (lt/session) 25.0 ± 3.6 24.5 ± 3.6 0.14 0.44
Qconv > 20lt (% sessions)* 89.9% 87.7% 0.57
Qconv/BSA (lt/session) 23.9 ± 3.5 23.4 ± 3.4 0.12 0.36
Qinf (lt/session) 22.3 ± 3.2 22.2 ± 3.6 0.67 0.74
Qb (ml/min) 329.3 ± 25.3 328.0 ± 24.3 0.62 0.19
Filtration Fraction (%) 32.6 ± 3.4 32.7 ± 4.1 0.79 0.25
FF > 40%* 3% 7% 0.06
TMP 20’ (mmHg) 124.1 ± 47.1 116.4 ± 43.0 0.07 0.94
%TMP 20’ > 250 mmHg* 3% 0% 0.10
TMP 240’ (mmHg) 228.4 ± 44.8 223.8 ± 45.0 0.19 0.72
%TMP 240’ > 300 mmHg* 7.8% 7.8% 0.99
End-treatment aPTT (sec) 34.7 ± 7.8 35.1 ± 8.3 0.67 0.89
Table 3  Medium and small molecule handling
OL-HDFst OL-HDFcit St vs Cit p T2-T0 
Paired 
means p
ß2 M pre (mg/l) 25.8 ± 5.5 25.4 ± 5.0 0.20 0.40
ß2 M RR (%) -76.0 ± 7.2 -76.2 ± 6.5 0.73 0.31
eKTV 1.33 ± 0.18 1.31 ± 0.19 0.38 0.32
Table 4  Pre-dialytic Acid–base and divalent ions
Ca++ values < 1 mmol/l: 7.1% in both OL-HDFst (n = 141) and OL-
HDFcit (n = 141). One value < 0.9 mmol/l in OL-HDFcit
OL-HDFst OL-HDFcit St vs Cit p T2-T0 
paired 
means p
pH 7.38 ± 0.06 7.38 ± 0.06 0.56 0.92
HCO3 
(mEq/l)
23.7 ± 1.8 23.4 ± 1.8 0.40 0.80
Ca++ 
(mmol/l)
1.11 ± 0.08 1.10 ± 0.08 0.37 0.86
PO4 (mg/
dl)
5.1 ± 1.4 5.3 ± 1.3 0.13 0.08
Mg (mg/dl) 2.20 ± 0.36 2.15 ± 0.37 0.01 0.43
iPTH (pg/
ml)
259.4 ± 136.8 269.4 ± 132.4 0.56 0.02
Alk Phos 
(UI/l)
93.2 ± 48.6 91.0 ± 45.9 0.53 0.62
Fetuin (ng/
ml)
4.4 ± 3.5 4.0 ± 2.9 0.25 0.88
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However, serum ß2 pre-treatment values did not change. 
The efficiency for small molecule clearance was assessed 
by eKTV measured by monitor-derived ionic dialysance and 
did not vary among procedures.
Biochemistry (Tables 4 and 5)
Pre-treatment acid–base parameters and  Ca++ values were 
not significantly different along the 3-month study period 
regardless of buffer (Table 4). The percentages of  Ca++ val-
ues below 1 mmol/l were 7.1% of the 141 determinations 
performed in both standard and citrate OL-HDFs and only 
one  Ca++ value was below 0.9 mmol/l during OL-HDFcit. 
There was a tendency to higher pre-treatment PO4 values 
and lower Mg values in OL-HDFcit in comparison with 
OL-HDFst. Fetuin and Alk Phos values did not change with 
time or between procedures. Although iPTH values were 
not significantly different along the 3-month study period 
regardless of buffer, there was a trend towards an increase 
in iPTH values in OL-HDFcit and a reduction in OL-HDFst. 
Dichotomizing the population according to the nominal CaD 
concentrations in OL-HDFcit (Table 5),  Ca++ values were 
higher and iPTH values lower in the 10 patients on CaD 1.65 
than in the 37 patients on CaD 1.5 mmol/l.
Discussion
In a dialysis population characterized by low-grade inflam-
mation and in a 3-month time span, acetate-free, 1 mmol 
citrate OL-HDF achieved lower IL-6 values than standard 
bicarbonate 3 mmol acetate OL-HDF. The hsCRP trend 
corroborated the IL-6 results. Interestingly, the reduction 
of inflammatory markers is associated with an increase in 
Klotho in OL-HDFcit. Acid–base and laboratory parameters 
surrogate outcomes of mineral bone disease did not vary, 
particularly when dialysate Ca 1.65 mmol/l was used. These 
results are due to the use of citrate and not to differences in 
applied technology since both experimental and comparison 
OL-HDFs were performed at the highest quality levels.
The anti-inflammatory effect of citrate was investigated 
in manifold biological systems. Citrate induced minor 
polymorphonuclear and platelet degranulation with reduc-
tion of oxidized LDL [11], decreased glycoxidation and 
lipid peroxidation products [12], reduced cell-free mito-
chondrial DNA marker of cellular damage [13] and reduced 
intra-dialytic synthesis of Pentraxin-3, a marker of dialysis 
bio-incompatibility associated with cardiovascular diseases 
[19]. Moreover, we recently demonstrated that switching 
from acetate to citrate buffer reduces systemic inflammation 
and prevents the harmful effects of the adipokine chemerin, 
e.g., a uremic toxin known to induce vascular dysfunction 
by targeting both endothelial and vascular smooth muscle 
cells [17]. However, regarding inflammatory circulating 
molecules, some studies reported positive results [13–17], 
while others showed negative results [18–20]. The com-
parison between these studies is difficult due to differences 
in the study design, the dialysis technique and the target 
cytokine. In our RCT, we focused on IL-6 for a number of 
reasons. IL-6 is more predictive of hard clinical outcomes 
than the other routine laboratory-based measures of inflam-
mation [36–38], it plays a pivotal role in the pathogenesis 
and progression of atherosclerosis [39] and it is implicated 
in the remodeling observed after myocardial infarction [40]. 
Moreover, a meta-analysis including more than 9000 patients 
demonstrated that circulating IL-6 levels are independently 
associated with a greater risk of cardiovascular mortality in 
the general elderly population [41]. In our study, IL-6 was 
measured at an external, qualified laboratory blinded to the 
procedures employed, and the trend of IL-6 in HDFs was 
evaluated by various statistical tests. These safeguards make 
us confident of the robustness of our results. As inflamma-
tion is among the surrogate markers of mortality, our data 
are in line with recent evidence on the safety of citrate on 
hard outcomes such as survival [29–32]. In this regard, it is 
interesting to note that in our study only one patient dropped 
out during OL-HDFcit, compared to five patients who did 
so during OL-HDFst. This result, however, is anecdotal 
because the study was not powered to investigate the clini-
cal safety of citrate dialysate in the long run.
To assess the clinical role of citrate, the comparability of 
the dialysis techniques employed is also relevant. Some of 
the previous studies included patients on both HD and HDF 
[17, 19, 20], the latter employed in pre- and post re-infusion 
with inadequate amount of convection [20]. When only HDF 
was challenged, the infusion was in pre- [14] or in post-
dilution without reporting the amount of convection [16]. 
These differences may well impact on results since, at vari-
ance with HD, HDF reduces systemic micro-inflammation 
[21–25] and only high convection volumes are associated 
with positive clinical outcomes [26–28]. Patient-related or 
dialysis center-related factors often prevent achieving the 
prescribed convection volumes [42]. In our study, average 
convective volume was particularly high, with 89% of treat-
ments fulfilling the current gold standards [26–28]. Linked 







Ca++ (mmol/l) 1.09 ± 0.09 1.13 ± 0.09 0.03
PO4 (mg/dl) 5.4 ± 1.4 4.9 ± 1.1 0.08
Mg (mg/dl) 2.13 ± 0.40 2.22 ± 0.59 0.29
iPTH (pg/ml) 292.7 ± 149.7 183.3 ± 111.7 0.01
Alk Phos (UI/l) 96.6 ± 48.5 70.5 ± 37.8 0.03
 Journal of Nephrology
1 3
to high convection was a commensurate ß2 M reduction rate, 
which however did not result in pre-treatment lower values 
of ß2 M. These optimal outcomes are due to the excellent 
technical practices of the dialysis centers involved in this 
study. Mean TMP at 20’ is well within the range of rec-
ommendations and excludes significant albumin loss and 
dialyzer clotting at the beginning of treatment besetting 
treatment efficacy [43]. Accordingly, average session TMP 
profile is reassuring with a low percentage of TMP values 
at 240’ exceeding 300 mmHg. The achieved treatment time 
is superimposable to the set time, which excludes interrup-
tion of treatments due to technical problems. Unlike other 
studies [4, 5], we did not find higher dialysis efficiency for 
small molecules with citrate. In those studies, citrate was 
used in HD while we tested it in OL-HDF. The particularly 
high convection achieved may have obscured any advantages 
on KT/V, e.g., a parameter influenced by diffusion. Moreo-
ver, we measured KT/V by ionic dialysance, a method that 
yields lower results than measurements based on the urea 
distribution volume.
Regional citrate causes anticoagulation chelating Ca with 
a consequent reduction of the ionized fraction and potential 
hypocalcemia [44]. However, the small amount of citrate in 
the dialysate (0.65-1 mmol/l, as per manufacturer) is one-
fifth of the standard concentration adopted in regional anti-
coagulation. We found higher serum  Ca++ and lower iPTH 
values in citrate OL-HDF with CaD 1.65 than with CaD 
1.5 (tab 5). Our results are in agreement with Molina et al. 
[16] and Perez-Garcia et al. data [45] and confirm the cur-
rent trend of increasing CaD when using citrate dialysate. 
However, this recommendation did not enter in the routine of 
all HD centers. Indeed, the largest RCT to date published on 
citrate included both CaD 1.5 and 1.65 mmol/l (20). It is rea-
sonable to hypothesize that the CaD of the citrate dialysate 
should be individualized based on the subject’s bone marker 
parameters. CaD 1.65 is suitable in subjects with serum Ca 
and PTH values in the low and high range of normality, 
respectively. Per contra, hypercalcemia or low serum iPTH 
levels or adynamic bone disease may benefit from lower 
CaD concentrations (32).
It should be pointed out that serum  Ca++ and iPTH 
fluctuations are just two of the players in the field. It is a 
time-honored achievement that most body citrate is in the 
bone tissue, it is released during bone resorption, it binds 
calcium ions in organic fluids, thus counteracting calcium-
phosphate precipitation in soft tissues [46]. Citrate may 
also take part in bone formation as it stabilizes the apatite 
nanocrystals in the bone [47]. While citrate is a low-molec-
ular weight inhibitor of calcification, fetuin A and Klotho 
are high molecular weight direct and indirect inhibitors of 
systemic calcification, respectively [33]. However, both are 
pleotropic molecules with diverse, even contradictory effects 
on different systems, brought about by interaction with a 
variety of receptors [48]. The stable serum levels of fetuin, 
the significant increase in soluble Klotho and the reduc-
tion of inflammatory parameters that we herein observed in 
OL-HDFcit is just hypothesis-generating, and further stud-
ies specifically addressing the role of citrate on propensity 
to tissue calcification are needed. Klotho gene is mainly 
expressed in proximal and distal tubular epithelial cells and 
acts as a co-receptor for FGF-23 exerting a biological role 
on mineral metabolism and protection against vascular cal-
cification. Moreover, Klotho deficiency has been associated 
with CKD progression and with the development of a pro-
senescent phenotype characterized by accelerated vascular 
aging. In subjects with normal renal function, serum con-
centrations and vascular expression of Klotho were down-
regulated in the presence of severe atherosclerotic lesions 
with a negative and significant correlation with inflamma-
tory parameters such as TNF-alpha, IL-6 and IL-10 [49]. 
Similar data were also observed in patients with end stage 
renal disease [50]. Furthermore, in hemodialysis patients, 
lower Klotho levels are associated with a pro-inflammatory 
state and with increased cardiovascular/cerebrovascular 
events and mortality regardless of other established risk fac-
tors [51, 52]. Recent studies further corroborated the role of 
Klotho in CKD-related inflammation and premature aging. 
On one hand, pro-inflammatory factors are responsible for 
the activation of NF-kB, the intracellular master control of 
inflammatory response, oxidative stress and apoptosis. In 
turn, NF-kB activation down-regulates Klotho expression. 
On the other hand, the anti-inflammatory activity of Klotho 
may be at least in part ascribed to its negative regulation of 
NF-kB with its attendant decreased production of inflamma-
tory mediators [53]. It was not the aim of this study to evalu-
ate whether the inflammatory state generates Klotho or, on 
the contrary, if Klotho is mainly responsible for hampering 
inflammation. However, our results suggest that OL-HFDcit 
may modulate the inflammatory response of chronic uremic 
patients by increasing Klotho as well.
We acknowledge some limitations of our study: we did 
not evaluate heparin doses, hence, we cannot discriminate 
the anti-flogistic effect of citrate and heparin per se [54]. 
However, the superimposable end-treatment aPTT values 
make us confident that heparin regimens did not vary dur-
ing either OL-HDFs, according to study protocol. Moreover, 
our study design prevents discriminating whether the anti-
inflammatory effect of citric acid-based dialysate is due to 
the absence of acetate [1, 3] or to the presence of citrate 
as such. We should have compared citrate with other non-
acetate buffers such as HCl. However, this latter dialysate 
was popular in the past but then its use gradually decreased.
In conclusion, notwithstanding the very high standards 
of both techniques tested in a population that did not show 
high levels of inflammation, OL-HDF citrate achieved lower 
serum levels of the pro-inflammatory marker IL-6 than the 
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standard procedure. Moreover, OL-HDF citrate was associ-
ated with a significant increase in the anti-inflammatory and 
anti-aging molecule Klotho. These results are not attributa-
ble to differences in the dialysis technology that was applied 
and may suggest a potential biological effect of citrate on 
CKD-associated inflammatory state.
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